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Sjögren-Larsson syndrome (SLS) is a rare neurometabolic syndrome caused by
deficient fatty aldehyde dehydrogenase. Patients exhibit intellectual disability,
spastic paraplegia, and ichthyosis. The accumulation of fatty alcohols and fatty
aldehydes has been demonstrated in plasma and skin but never in brain. Brain
magnetic resonance imaging and spectroscopy studies, however, have shown
an abundant lipid peak in the white matter of patients with SLS, suggesting
lipid accumulation in the brain as well. Using histopathology, mass spectrome-
try imaging, and lipidomics, we studied the morphology and the lipidome of a
postmortem brain of a 65-year-old female patient with genetically confirmed
SLS and compared the results with a matched control brain. Histopathological
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analyses revealed structural white matter abnormalities with the presence of
small lipid droplets, deficient myelin, and astrogliosis. Biochemically, severely
disturbed lipid profiles were found in both white and gray matter of the SLS
brain, with accumulation of fatty alcohols and ether lipids. Particularly, long-
chain unsaturated ether lipid species accumulated, most prominently in white
matter. Also, there was a striking accumulation of odd-chain fatty alcohols and
odd-chain ether(phospho)lipids. Our results suggest that the central nervous
system involvement in SLS is caused by the accumulation of fatty alcohols
leading to a disbalance between ether lipid and glycero(phospho)lipid metabo-
lism resulting in a profoundly disrupted brain lipidome. Our data show that
SLS is not a pure leukoencephalopathy, but also a gray matter disease. Addi-
tionally, the histopathological abnormalities suggest that astrocytes and
microglia might play a pivotal role in the underlying disease mechanism, possi-
bly contributing to the impairment of myelin maintenance.
KEYWORD S
brain, ether lipids, fatty aldehyde dehydrogenase, lipidomics, mass spectrometry imaging, odd-
chain fatty alcohols, pathology, phospholipids, Sjögren-Larsson syndrome
1 | INTRODUCTION
Sjögren-Larsson syndrome (SLS; OMIM #270200) is a
neurometabolic disorder caused by fatty aldehyde dehy-
drogenase (FALDH) deficiency1 due to biallelic muta-
tions in ALDH3A2.2 Patients suffer from intellectual
disability, spastic diplegia, ichthyosis, and retinopathy.3,4
The FALDH deficiency results in accumulation of fatty
aldehydes and fatty alcohols in plasma and skin.5,6
FALDH is involved in the degradation of leukotrienes,
which leads to increased levels of leukotriene B4 in
patients.7 Furthermore, FALDH plays a role in phytol
metabolism, converting phytenal into phytenic acid,
apparently without accumulation of phytol or its degra-
dation products in SLS patients.8 Brain magnetic reso-
nance (MR) imaging studies show a white matter
disorder,9,10 and proton MR spectroscopy reveals abnor-
mal signals between 0.8 and 1.6 ppm,10 which reflect
abnormal lipid accumulation.9 Only a few postmortem
reports on SLS are available, but in none of these
patients, the diagnosis was biochemically or genetically
confirmed.11-14 Consequently, the underlying disease
mechanisms causing the brain disorder in SLS, including
the most important lipids involved, are not yet known.
Lipids comprise half of the human brain dry weight.
They provide membrane structure and are required for
membrane trafficking, signal transmission, and syn-
aptogenesis.15 Cholesterol and phospholipids are the
main membrane lipids. Phospholipids have a phosphate-
containing head-group at the sn-3 position of a glycerol
backbone, and one or two fatty acyl-groups linked via an
ester bond. They are subdivided in subclasses based on
the nature of the head group (ie, phosphatidylethanol-
amine contains an ethanolamine head-group, whereas
phosphatidylcholine contains a choline head group).15
Ether phospholipids, including plasmalogens, constitute
a special phospholipid class, characterized by the pres-
ence of an ether or a vinyl ether at the sn-1 position of
the glycerol backbone instead of an ester (Figure 1).16
The most abundant lipid species in the human brain,
apart from cholesterol, are phospholipids with phosphati-
dylcholine (PC), phosphatidylethanolamine (PE), and
phosphatidylserine (PS) as the three most abundant
classes.17
We studied the postmortem brain of a 65-year-old
female patient with genetically confirmed SLS using
targeted as well as untargeted lipidomic approaches in
combination with morphological analyses. Our results
SYNOPSIS
The brain disorder in Sjögren-Larsson syndrome
(SLS) is explained by a severely disrupted lipid
profile in both white and gray matter with accu-
mulation of fatty alcohols and ether lipids and
histopathological abnormalities in astrocytes and
microglia.
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show a severely disturbed lipid profile in the SLS brain
with accumulation of various species of fatty alcohols,
ether(phospho)lipids, and triacylglycerols in both white
and gray matter, and confirm the presence of structural
white matter abnormalities.
2 | MATERIALS AND METHODS
Materials and methods are described in the Supporting
information.
3 | RESULTS
3.1 | ResultsHistopathology of the SLS
brain
The SLS brain (weight 1347 g) was macroscopically nor-
mal (Figure 2A-C). Microscopically, lack of myelin with
tissue rarefaction was seen in hemispheric deep white
matter and capsulae (Figure 2D,E), whereas the U-fibers
and corpus callosum were better preserved without signs
of demyelination. Oligodendrocyte numbers were not
FIGURE 1 Relevant lipid
structures and nomenclature.
Lipid species are designated by
their class followed by the sum of
the carbon atoms in the fatty acid
side chains and the total amount
of double bonds. The main
structure is shown for, A,
phospholipids, in this case a
phosphatidylcholine species (PC)
with two fatty acids that have a
total of 38 carbon atoms and 5
double bonds, for example, PC
(38:5), B, ether phospholipids
contain a fatty alcohol on the sn-
1 position of the glycerol
backbone which results in an
ether bond [O]. The species
shown here has a choline
headgroup and therefore is a
plasmanylcholine (PC[O]), and
with this fatty acid/alcohol side
chains is termed PC[O](36:4). A
special class of ether
phospholipids, plasmalogens,
contain a vinyl-ether on the sn-1
position (extra double bond
indicated in a dashed line). With
the choline headgroup this class
is called plasmenylcholines, in
this case PC[O](36:5). C,
Triacylglycerols (TG) are the
condensation product of three
fatty acids and one glycerol
molecule, here TG(50:1),
whereas, D, 1-alkyl-2,3-
diacylglycerols, in analogy to
ether phospholipids, have a
ether-linked fatty alcohol on the
sn-1 position (TG[O]), in this case
TG[O](50:1)
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diminished and scattered axonal spheroids were found
(Figure 2D-F). A diffuse isomorphic astrocytic gliosis was
present, and some microglia had a phagocytic
morphology (Figure 2G,H). Around blood vessels cluster-
ing macrophages contained pigmented PAS-positive iron-
negative material. These pathological changes were more
FIGURE 2 Legend on next page.
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evident in occipital white matter. In the white matter,
smaller blood vessels had thickened walls with relative
loss of smooth muscle cells in the tunica media and
thickened tunica adventitia (Figure 2I). The cerebral
cortex was only mildly gliotic, without neuronal dropout
or microglia activation. Basal nuclei, thalamus, and hip-
pocampus were unaffected (Figure 2J). The long white
matter tracts in the brainstem and spinal cord also
FIGURE 2 Neuropathology of SLS. A, Whole coronal slice of the right hemisphere at the level of the pulvinar shows no normal
trophism of the cortex and of the white matter. B,C, Whole coronal mounts at the same level show that the periventricular and deep
hemispheric white matter is pale (B, hematoxylin and eosin [H&E]; C, Kluver stain for myelin combined with periodic acid Shiff), whereas
the U-fibers are relatively better preserved. D, H&E stain of the occipital white matter confirms white matter pallor and reveals preservation
of oligodendrocyte numbers and presence in the neuropil of yellowish lipid droplets (inset). E, Stain for the major myelin protein proteolipid
protein (PLP) shows that white matter pallor is due to decreased amounts of myelin. F, stain for the pan-oligodendrocytic marker Olig2
further confirms that oligodendrocytes are not depleted. G, Stain against the astrocyte marker glial fibrillary acidic protein (GFAP) reveals a
diffuse isomorphic astrogliosis. H, stain against the microglia/macrophage marker CD68 shows that cells with a phagocytic morphology are
clustered around blood vessels. I, the histochemical stain Trichrome shows blood vessel wall changes consistent with hyalinosis, including
thickening of the walls and loss of cells in the tunica media. J, H&E stain of the occipital cortex shows normal organization with no loss of
neurons. K, PLP stain of the descending tracts in the brainstem shows reduced myelin amounts. L, In the same areas, the CD68 stain reveals
presence of normal numbers of microglia that do not show an ameboid activated aspect. M,N, H&E stain (M) and immunohistochemistry
against high-molecular weight neurofilaments (NF, N) reveals loss of Purkinje cells in the cerebellar cortex with presence of empty baskets.
O, Stain against the Bergmann glia marker S100β shows that Purkinje cell dropout corresponds with proliferation of Bergmann glia, some of
which are abnormally translocated to the molecular layer
FIGURE 3 Fatty alcohols and lysophosphatidylcholine etherphospholipid abundancies in SLS and control brain tissue. A, Mean
concentrations of fatty alcohols are shown in both white and gray matter of SLS and control brain tissues. Fatty alcohols were measured in
four separate samplings of brain (mean, SEM). B, Mean abundancies of individual LPC[O]s as measured with untargeted lipidomics; brain
samples were measured in triplicate using three pieces of the same brain samples that were processed independently. LPC[O],
lysophosphatidylcholine etherphospholipid; SLS, Sjögren-Larsson syndrome
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showed deficient myelin, however, without microglia or
astrocytic activation (Figure 2K,L). The cerebellar white
matter was better preserved compared to the cerebral
areas; however, activated microglia and scattered macro-
phages were found in perivascular spaces. In cerebellar
cortex, a mild dropout of Purkinje cells and granular neu-
rons were seen, with some degree of mislocalization of
the Bergmann glia nuclei to the molecular layer (Fig-
ure 2M-O). No white matter pathology was found in the
optic nerve, optic chiasm, and optic tract.
3.2 | Free fatty alcohols and fatty
aldehydes
The total free fatty alcohols as a group (C16-24) were
increased in SLS brain compared to control brain by 4.1-
fold in white matter and 3.8-fold in gray matter. A similar
fatty alcohol profile was observed for white and gray mat-
ter of the SLS brain but fatty alcohols accumulated in
much higher concentrations in white matter than in gray
matter (Figure 3A). The chain lengths of the accumulat-
ing alcohols ranged from C18 to C24 and comprised both
even- and odd-length chains. Notably, the long-chain
fatty alcohols C21 to C24, both saturated and mono-
unsaturated were highly elevated in SLS brain, more so
in white matter than gray matter. In SLS white matter,
this subgroup of fatty alcohols was increased by 17-fold
over control brain. C23-fatty alcohols were the most
abundant species in both white and gray matter, with
fold changes of respectively 166 and 76. There was no
parallel accumulation of free very long chain fatty acids.
Surprisingly, although small amounts of free fatty alde-
hydes (C14:0, C16:0, C17:0, C18:0, and C18:1) were pre-
sent in both brains, there was no accumulation of
aldehydes in the SLS brain (data not shown).
3.3 | Lipid analysis
The lipidome of white and gray matter samples of SLS
and control brain was using untargeted lipidomics. A
total of almost 1700 individual lipid species from 33 dif-
ferent lipid classes could be evaluated by our lipidomics
technique. The most abundant lipid classes in the control
brain in descending order are cholesterol and its esters,
DG, PE[O], PC[O], DG[O], TG, CL, BMP, LPE[O], and
LPC[O] (Figures 3B and 4). The profile was similar for
white and gray matter. Most individual lipid species were
found in remarkably similar concentrations in SLS and
control brain, suggesting that the quality of both brain
samples and the analysis was comparable. The following
major classes, including subspecies, did not change
significantly when comparing SLS and control brain:
sphingolipids; ceramides, ceramide-1-phosphates,
hexosylceramides (HexCer), lactosylceramides, sulfatides,
hydroxysulfatides, sphingosines, sphingosine-1-phos-
phates and sphingomyelins, and phospholipids; (lyso)
phosphatidic acids, (lyso)phosphatidylglycerols,
phosphatidylinositols, phosphatidylserines, and mono-
and dilysocardiolipins.
Several lipid classes accumulated in SLS brain, both
in white and gray matter (Figure 4). The majority of the
accumulating lipid classes were ether lipids (DG[O], TG
[O]) and ether phospholipids (mainly PC[O], LPC[O]),
whereas the corresponding non-ether lipid levels were
not elevated (DG, PC, LPC), or even reduced, with the
exception of TG levels in white matter which were higher
in SLS. Surprisingly, the ethanolamine ether phospho-
lipids, PE[O] and LPE[O] as a group, were unchanged in
both SLS white and gray matter. To investigate if the
changes in the ether phospholipid levels impacted the
plasmanyl/plasmenyl distribution (ie, ether phospholipid
vs plasmalogen), we compared the levels of representa-
tive and well detected PE[O] and PC[O] species with-
and without hydrochloric acid treatment. This treatment
hydrolyses the alkenyl-bond (ie, plasmenyl) but not the
alkyl (ie, plasmanyl) species on the sn-1 position. The
plasmanyl/plasmenyl ratio was consistently unchanged
for both PC[O] and PE[O] when comparing SLS and con-
trol brain for both white and gray matter (Supporting
information). Other non-ether phospholipid classes
including PS, LPE, and PE also showed a trend toward
lower levels in SLS white matter, respectively, 77%, 59%,
and 55% of the control tissue abundancy. In gray matter,
CE and DG showed a trend toward lower levels in SLS,
with, respectively, 51% and 64% abundancy of the control
tissue. The concentration of accumulating ether lipids
was highest in SLS white matter. The highest fold change
(FCSLS/Control) was 93 for TG[O]. Other grossly elevated
lipid classes were LPC[O] (FCSLS/Control = 9.0), DG[O]
(FCSLS/Control = 6.8), and PC[O] (FCSLS/Control = 3.7). The
lipid classes that contributed most to the abnormal lipid
accumulation in the SLS white matter on a molar basis
are in descending order CE, PC[O], DG[O], LPC[O], TG
[O], and TG which was similar to what was observed in
SLS gray matter although the concentration of the accu-
mulating lipid classes was less pronounced in gray matter
(Figure 4).
3.3.1 | Fatty alcohols in lysoforms of
ether phospholipids
Fatty alcohols are used for the synthesis of the 1-O-alkyl
chain in ether (phospho)lipids. Figure 3B shows the
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abundance of LPC[O] species in control- and SLS brain.
In these lipids, long-chain fatty alcohol species pre-
dominated both in white and gray matter. A similar pat-
tern of carbon chain lengths occurred in fatty alcohols
and LPC[O]'s and to a lesser extent in LPE[O]'s. In LPC
[O], the chain length of the accumulating species varied
between C16-C24 and, somewhat unexpectedly, the most
abundant LPC[O] was LPC[O] 23:0. LPC[O] 23:1 accu-
mulated to a lesser extent than in its fatty alcohol coun-
terpart. Collectively, these data indicate that the pattern
of accumulating fatty alcohol species is very similar to
the distribution of LPC[O] species and that very long-
chain, odd-chain fatty alcohols are the main accumulat-
ing fatty alcohols.
3.3.2 | Individual lipid subspecies
To evaluate which specific lipid species predominantly
accumulate in SLS brain, we considered individual lipids
with a fold change >3 in SLS compared to control and a
difference in relative abundance >10. A total of 175 indi-
vidual lipids from 11 lipid classes fulfilled these criteria
in white matter, compared to 104 individual lipids from 9
lipid classes in gray matter (Supporting information). For
most lipid classes, the accumulating lipid subspecies
overlapped between white and gray matter (LPC[O], PC
[O], DG[O], TG[O]). Of all TG[O] species detected in SLS
white matter, 69% had more than 54 carbons in the fatty
acid side chains (more than three C18). In SLS white
matter, the individual lipid species with the highest fold-
change compared to control were CE(24:4) (FCSLS/Con-
trol = 10.9), PC[O](32:0) (FCSLS/Control = 7.1), LPC[O]
(23:0) (FCSLS/Control = 84.2), and TG[O](52:2) (FCSLS/Con-
trol = 127). In gray matter, these were CE(24:5) (FCSLS/
Control = 3.8), PC[O](39:0) (FCSLS/Control = 250.5), LPC[O]
(23:0) (FCSLS/Control = 118.2), and DG[O](39:1) (FCSLS/
Control = 13.8). In almost all cases, the abundance of accu-
mulating ether lipid species in SLS was clearly higher in
white than in gray matter, with exception of PE[O].
Remarkably, the abundance of selected odd-chain PE[O]
species, however, was clearly higher in SLS gray matter
than in white matter, namely PE[O](45:8), PE[O] (45:7),
and PE[O](45:6), accumulated in gray matter with fold
changes between 14 and 360 but not in white matter
(Supporting information). When comparing the sum of
all PE[O] species between SLS and control, no large
increase was seen as opposed to other ether lipid species.
FIGURE 4 Abundancies of different lipid classes in SLS and control brain tissue. Totals of the quantitatively most important lipid
species per major class for control and patient white and gray matter; the mean abundance is shown; Brain samples were measured in
triplicate using three pieces of the same brain samples that were processed independently. CE, cholesteryl ester; DG, diacylglycerol; DG[O],
1-alkyl-2-acylglycerol; PC, phosphatidylcholine; (L)PC[O], (lyso)phosphatidylcholine etherphospholipid; PE, phosphatidylethanolamine; (L)
PE[O], (lyso)phosphatidylethanolamine etherphospholipid; SLS, Sjögren-Larsson syndrome; TG, triacylglycerol; TG[O], 1-alkyl-2,3-
diacylglycerol
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In gray matter, 26 PE[O] species fulfilled the criteria of a
fold change >3 and an abundance >10 compared with
control brain. Almost all of these PE[O] species (n = 25
of 26) contained (very) long fatty acids/alcohols with a
total of carbon atoms ranging from 39 to 47 and were
polyunsaturated (17 out of 24 had 5 or more double
bonds). Although the sum of the PE[O] species was not
increased in SLS white matter, individual long-chain PE
[O] species did accumulate when compared to control,
even more than in gray matter (seven PE[O] species with
FIGURE 5 Mass spectrometry imaging-based distributions of ether-phospholipids in SLS and control brain tissue. A, Overview of the
tissue morphology. Gray matter areas from the SLS brain (red) and control (green), as well as white matter areas from the SLS brain (purple)
and control brain (cyan) were measured. B, In-situ distributions of PC(O-32:0) detected as both Na+-adduct (m/z 742.574) and K+-adduct
(m/z 758.558). C, In-situ distributions of PC(O-39:0) detected as both Na+-adduct (m/z 840.683) and K+-adduct (m/z 856.658). PC[O],
phosphatidylcholine etherphospholipid; SLS, Sjögren-Larsson syndrome
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chain length 46 and 47 and 5-8 double bonds; Supporting
information). The total CE level in control white matter
was only moderately elevated in SLS brain, but this was
not seen in gray matter (Figure 4). Remarkably, specific
CE species with polyunsaturated long- and very-long-
chain acyl-groups were highly elevated in SLS white mat-
ter (20:2, 22:3, 24:5, 22:5, 24:4) and to a lesser extent also
in gray matter (Supporting information).
3.4 | Mass spectrometry imaging
During sectioning of brain tissue for mass spectrometry
imaging, two blocks from each brain were prepared; one
containing mostly gray matter, the other containing
mostly white matter. As expected, large differences in the
lipid content were visible between white and gray matter,
both in the SLS and control tissues (Supporting informa-
tion). A total of 1872 m/z features were detected from the
overall mass spectrum (including both white and gray
matter regions, from SLS and control tissues). We
searched for the most discriminating peaks between the
SLS and control tissues. The lipid features that distin-
guish the SLS and control profile could be tentatively
identified as PE[O] and PC[O] species. The differentiat-
ing lipid species were low in abundance, but had a
unique presence in the SLS patient brain. PC[O](32:0)
and PC[O](39:0) clearly accumulated in the SLS brain
(Figure 5). This is in line with the biochemical data from
the untargeted lipidomics approach in the previous sec-
tion and in Supporting information. The same holds true
for the accumulation of individual PE[O] species.
4 | DISCUSSION
Our study describes a comprehensive biochemical as well
as histopathological evaluation of the postmortem brain
of a patient with genetically confirmed SLS; the results
contribute to our understanding of SLS, and illustrate the
power of novel techniques to clarify the biochemical
abnormalities of the brain in neurometabolic disorders.
The white matter of the SLS brain showed lack of
myelin and perivascular macrophages containing
pigmented lipoid material, with a posterior hemispheric
predominance. The absence of numerous, scattered mac-
rophages in the parenchyma argues against ongoing
demyelination and rather suggests an impairment in the
process of myelin maintenance. The white matter abnor-
malities and accumulating lipoid material correspond to
the results of cerebral MR imaging and spectroscopy in
living SLS patients.10 Interestingly, in the more affected
occipital lobes, we also found astrocyte and microglia
activation, suggesting that the disease mechanisms
underlying the leukodystrophy are ongoing. Dysfunction
of astrocytes and microglia could contribute to an impair-
ment in myelin maintenance.18 The direct involvement
of these cell types is in line with the findings in previous
retinal studies in SLS, which suggested a similar role for
Müller cells, the retinal counterpart of cerebral
astrocytes.19
It is known that fatty alcohols accumulate in body
fluids of SLS patients,1 but their accumulation in the cen-
tral nervous system has never been shown. We found a
striking accumulation of fatty alcohols in SLS brain with
a predominance of C18-C24 chain length species. Inter-
estingly, although the C18:0 alcohol was elevated, the
C16:0 alcohol was not. This long-chain fatty alcohol pat-
tern differs from that seen in SLS plasma, cultured fibro-
blasts and keratinocytes in which only C16-C18 fatty
alcohols accumulate.5,20 The longer chain fatty alcohols
(C21-C24) therefore likely are unique to brain. Long-
chain fatty alcohols are synthesized from their
corresponding fatty acids of similar chain length but can
also be formed in the fatty alcohol cycle by reduction of
aldehydes that originate from catabolism of metabolites,
which will be discussed below.21,22 The fatty acyl-CoA-
reductase (FAR) enzyme in mouse and bovine, involved
in the de novo synthesis of fatty alcohols, has highest
activity with C15-C18 acyl-CoA substrates and very low
activity with C20-C22-acyl-CoA substrates.23,24 Humans
possess two distinct FAR enzymes (FAR1 and FAR2); it
is unknown which of these two enzymes is responsible
for synthesizing the longer C21-C24 alcohols identified in
SLS brain, and whether or not they are synthesized via
this pathway at all.25 Nevertheless, the normal fatty acid
composition of the SLS brain argues that the accumula-
tion of the fatty alcohols is not due to an increase in their
rate of synthesis via either FAR1 or FAR2. Another
potential source of fatty alcohols is the catabolism of dif-
ferent metabolites that lead to the production of fatty
aldehydes via the fatty alcohol cycle. Fatty aldehydes
arise from the degradation of plasmalogens, sphingosine-
1-phosphate, branched-chain fatty acids and 2-hydroxy-
fatty acids (Figure 6A).22,26 Aldehydes that are usually
oxidized to fatty acids by FALDH would accumulate and
be reduced to fatty alcohols, a phenomenon that was pre-
viously observed in SLS.1 In this respect, the predominant
accumulation of the odd-chain C23-alcohol was intrigu-
ing and unexpected. We speculate that this originates
from the breakdown of 2-hydroxy-fatty acids derived
from sphingolipids carrying these 2-hydroxy-fatty acids,
which are very abundant in brain, especially in white
matter.17,27 When liberated, 2-hydroxy-fatty acids are
activated to their corresponding CoA-ester and the
enzyme 2-hydroxyacyl-CoA lyase 1 cleaves this molecule
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FIGURE 6 Legend on next page.
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yielding formyl-CoA and an n-1 aldehyde.28 In brain, the
most abundant 2-hydroxy-fatty acid is C24,27 which
results in the formation of C23-aldehyde when broken-
down via this route (Figure 6B). As FALDH has the abil-
ity to metabolize aliphatic aldehydes ranging from 6- to
24-carbons long, with substrate specificity toward long-
chain fatty aldehydes we believe that C23-aldehyde could
also be a substrate for FALDH and that this thus accumu-
lates in SLS.29,30 FALDH functions as part of a complex
that, together with fatty alcohol dehydrogenase, sequen-
tially converts fatty alcohols to fatty aldehydes and fatty
acids.1,31 Since fatty alcohols are metabolic precursors for
synthesis of ether lipids, it is likely that the accumulation
of LPC[O] and TG[O] in SLS brain is a direct conse-
quence of increased amounts of fatty alcohol substrates
(Figure 6B) and that this distribution reflects the accumu-
lating alcohols and those resulting from reduction of cat-
abolically formed aldehydes. There was no increase in
plasmalogens in SLS brain based on the dimethyl acetal
peaks seen on fatty acid analysis. Although the C18:0
alcohol accumulated in the SLS brain and is a substrate
for plasmalogen synthesis, it does not seem to drive the
synthesis of plasmalogens by itself. This was supported
by the lipidomics experiment which showed comparable
levels of plasmenyl-species in SLS and control brain
(Supporting information).
We showed that the SLS brain lipidome is profoundly
altered as fatty alcohols cause accumulation of almost all
ether lipid classes in both white and gray matter with a
concomitant reduction in non-ether lipids. The accumu-
lating fatty alcohols most likely drive the enhanced syn-
thesis of ether lipids and etherphospholipids with a
characteristic pattern that is likely dictated by the tissue-
dependent aldehydes that are normally processed by
FALDH (Figure 6). Ether lipids, including plasmalogens,
are ubiquitously found throughout human tissues and
are known to be especially important in brain, heart and
spleen.16 For most accumulating ether(phospho)lipid
classes, the concentration in SLS white matter was much
higher than in SLS gray matter (Figure 4). The neutral
ether lipid and ether phospholipid classes with the
highest fold changes between SLS and control, both in
white and gray matter, were DG[O], TG[O], PC[O], and
LPC[O]. The TG[O] increase was especially remarkable
as TG[O] species normally are present in low levels in
the brain. The accumulating DG[O] is probably
converted to TG[O] as the amount of CDP-ethanol-
amine/CDP-choline generated by the Kennedy pathway
needed for the conversion of DG[O] to PE[O] and PC
[O], respectively, is limiting. Alternatively, the altered
fatty alcohol/fatty acid composition of DG[O] could be
incompatible with the substrate specificities of down-
stream biosynthetic enzymes. TG[O] is the most proxi-
mal metabolite to channel accumulating DG[O], the
primary product of ether lipid biosynthesis before
headgroups are added. Remarkably, PE[O] and LPE[O]
were not significantly increased as a group in the SLS
brain. Brain contains high PE[O] content, especially
white matter, and 50% to 100% of PE[O] are
plasmalogens.32 The plasmalogen synthesis is regulated
by post translational degradation of FAR1,33 which is the
rate-limiting enzyme for fatty alcohol production from
acyl-CoAs. As the supply of fatty alcohols is high in SLS,
plasmalogen synthesis will proceed normally, which
leads to degradation of FAR1 that in turn limits PE[O]
production. This possibly explains the relatively normal
levels of PE[O] in SLS brain. If, as we suggest above,
fatty alcohols are formed from reduction of aldehydes
originating from catabolism of 2-hydroxy-fatty acids,
sphingosine-1-phosphate and plasmalogens, this forma-
tion is not FAR1-regulated and represents an uncon-
trolled influx of fatty alcohols into ether lipid synthesis
which could explain the expansion of the ether lipid pool
in SLS (Figure 6).
FIGURE 6 Proposed origin of accumulating ether lipids in SLS. A, Etherphospholipid metabolism in the control brain (upper panel),
and the SLS brain (lower panel). Dihydroxyacetone phosphate and a fatty alcohol is converted to alkylglycerol in the peroxisome after which
alkylglycerol is acylated to form 1-alkyl-2-acylglycerol (DG[O]). DG[O] can be converted to PE[O] and PC[O] by condensation with CDP-
ethanolamine and CDP-choline, forming plasmanyl-PE and plasmanyl-PC. Creation of a vinyl-ether by desaturation, yields plasmenyl-PE/
PC. Collectively the plasmanyl- and plasmenyl forms are referred to as plasmalogens. DG[O] can also be acylated yielding 1-alkyl-2,3-
diacylglycerol (TG[O]). Catabolic aldehydes are shown which normally are converted to fatty acids by FALDH. In case of FALDH deficiency
in SLS, accumulating fatty aldehydes are converted to fatty alcohols which are then incorporated in the ether-(phospho)lipids DG[O], TG
[O], PC[O], and PE[O]. B, Hypothetic metabolic pathway explaining the formation and accumulation of odd chain fatty alcohols and odd-
chain etherlipid and etherphospholipid species in the SLS brain. The accumulation of these odd chain lipid species is explained using the
example of the conversion of a C24-2-hydroxy containing sphingolipid. After liberation of its fatty acyl chain and activation by CoA-addition
a C24-2-OH-CoA results. It is subsequently cleaved by 2-hydroxyacyl-CoA lyase 1 yielding formyl-CoA and a C23-aldehyde. Due to the
FALDH deficiency, this C23-aldehyde is reduced to its corresponding alcohol and incorporated into etherlipids and etherphospholipids. DG
[O], 1-alkyl-2-acylglycerol; FALDH, fatty aldehyde dehydrogenase; FAR1, Fatty Acyl-CoA Reductase 1; (L)PC[O], (lyso)phosphatidylcholine
etherphospholipid; PE[O], phosphatidylethanolamine etherphospholipid; SLS, Sjögren-Larsson syndrome; TG[O], 1-alkyl-2,3-diacylglycerol
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The accumulation of TG[O] has also been seen in cul-
tured SLS keratinocytes,20 raising the possibility that this
unique lipid profile links the pathogenesis of brain and
skin symptoms that are so characteristic of this disease.
The critical functions of these two organs depend on the
formation of multilamellar membranes in myelin and in
the stratum corneum. In SLS skin, ultrastructural studies
demonstrate that these stacked membranes are reduced
in number and interrupted by lipid deposits, resulting in
a leaky epidermal water barrier and the dry scaly appear-
ance of ichthyosis.34 Myelin membranes may be similarly
perturbed by accumulation of these same lipids.
In addition to the abnormal ether phospholipid
metabolism, neutral lipid metabolism was also disturbed
in the SLS brain. We found increased concentrations of
TG and CE which, in addition to TG[O], may also con-
tribute to the “lipid peaks” on brain MR spectra of SLS
patients and the lipid droplets seen in the histological
study of the SLS brain. Patients with other disorders that
lead to TG accumulation, that is, defects in DDHD2 and
Chanarin-Dorfman syndrome, have similar lipid reso-
nances in brain MR spectra.35,36
An abnormal low concentration of ether lipids is well
known in some peroxisomal diseases with obvious neuro-
metabolic consequences for the brain.36 In contrast,
increased concentrations are found in SLS. Recently, Vaz
et al described PCYT2 mutations that also heavily impact
ether (phospho)lipid biosynthesis.37 Patients developed a
progressive para- or tetraparesis with intellectual disabil-
ity. In line with the metabolic role of the PCYT2 enzyme
(catalyzing the rate limiting step of CDP-ethanolamine
biosynthesis for both PE and PE[O] [see also Figure 6]),
lipidomics in fibroblasts showed significant accumulation
of neutral lipids (TGs), ether lipids (DG[O], TG[O]), and
ether phospholipids (LPC[O], PC[O]). The fibroblast lipid
profile in PCYT2 deficiency is reminiscent of that found
in SLS brain. The brain lipid profile in patients with
PCYT2 deficiency has not been analyzed but specific dif-
ferences with SLS may be anticipated.
The levels of the regular phospholipids PC, PS, PI,
PG, and PE and their lyso-forms were, if at all, mildly
affected in SLS brain. This is to be expected as fatty alco-
hols do not play a role in the biosynthesis of these phos-
pholipids. Some of these phospholipids, like PS, LPE and
PE even showed a tendency toward a decreased concen-
tration in SLS which could be caused by the consumption
of CDP-ethanolamine/CDP-choline to synthesize PE[O]
and PC[O]. Another possible explanation might be fatty
aldehyde toxicity, causing inactivity of specific enzymes
responsible for the production of these lipids. This mech-
anism was described in a mouse study in SLS, where the
enzymatic activity of fatty acid 2-hydroxylase (FA2H
activity) was affected by fatty aldehyde accumulation.38
We detected no increase in free fatty aldehydes in the
SLS brain and very long chain aldehydes were not seen.
The storage time of the brain samples before analysis
may have played a role in this. It is possible that these
highly reactive lipids have formed covalent adducts with
amino-containing molecules and thus escape detection39
or were metabolized to fatty alcohols.40 Lastly, we did not
see any leukotrienes and phytol, lipids that have been
implicated in SLS pathophysiology. Phytol is probably
processed in the liver and may never reach the brain.41
Leukotrienes are biologically very active lipids and pre-
sumably have concentrations below the detection limit
and are not detected in our lipidomics platform.
The main limitation of this study is the fact that only
one SLS brain and one replica as control could be
included. Obtaining a single SLS-brain that also was
suited to perform biochemical studies was a unique
opportunity. Equally so it has been very hard to obtain
suitable control brain tissue (with same sex, age, no brain
disease, and the brain postmortem not processed in for-
malin or otherwise).
In conclusion, we have found a severely disturbed
lipid profile in both white and gray matter of the SLS
brain, affecting both neutral ether lipids and ether phos-
pholipids along with changes in neutral lipid metabolism.
Taken together our data suggest that the brain disorder
in SLS results from the accumulation of many different
lipid species, especially fatty aldehydes, fatty alcohols, tri-
glycerides and ether (phospho)lipids. Our data show that,
at the biochemical level, SLS is not only a white matter
but also a gray matter disease. Additionally, the histo-
pathological study suggests that astrocyte dysfunction
might play a pivotal role in the underlying disease mech-
anism, especially contributing to an impairment of mye-
lin maintenance.
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